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Introduction
Human adults contain nearly one trillion blood PLTs in circula-
tion. These small (2–3 µm), anuclear cells have a highly orga-
nized cytoskeleton, unique receptors, and specialized secretory 
granules. Among their primary functions, PLTs serve as the 
“Band-Aids” of the bloodstream and respond to blood vessel 
injury by changing shape, secreting their granule contents, and 
aggregating to form a PLT clot. PLTs also play secondary roles 
in lymphatic development and inflammation (Smyth et al., 
2009) by expressing immunomodulatory molecules and cyto-
kines with which they interact with various cells of the immune 
system (Semple et al., 2011). Among their most recognized and 
least understood immunomodulatory functions, PLTs express mul-
tiple members of a family of pattern recognition receptors called 
toll-like receptors (TLRs). TLRs have been best characterized 
in neutrophils, macrophages, and dendritic cells and promote 
immune activation in response to conserved molecular motifs 
expressed by pathogens (Janeway and Medzhitov, 2002). Al-
though human and mouse PLTs express TLRs 1–9, our current 
understanding of TLR function in PLTs is limited to TLRs 1–6, 
which are typically expressed on the PLT surface and thought 
to trap bacteria for elimination by professional phagocytes 
(Andonegui et al., 2005; Aslam et al., 2006; Clark et al., 2007). 
Less understood is the role of TLR9, which is expressed in the 
endosomes of monocytes, macrophages, and plasmacytoid den-
dritic cells and is thought to act as a receptor for unmethyl-
ated CpG islands found in bacterial and viral DNA (Hennessy 
et al., 2010).
Although reported to localize internally in PLTs, neither 
the site nor function of subcellular TLR9 is currently known 
(Aslam  et  al.,  2006).  In  macrophages  and  dendritic  cells, 
H
uman and murine platelets (PLTs) variably express 
toll-like receptors (TLRs), which link the innate and 
adaptive immune responses during infectious in-
flammation and atherosclerotic vascular disease. In this 
paper, we show that the TLR9 transcript is specifically up-
regulated during pro-PLT production and is distributed to 
a  novel  electron-dense  tubular  system-related  compart-
ment we have named the T granule. TLR9 colocalizes with 
protein disulfide isomerase and is associated with either 
VAMP 7 or VAMP 8, which regulates its distribution in 
PLTs on contact activation (spreading). Preincubation of 
PLTs with type IV collagen specifically increased TLR9 and 
CD62P surface expression and augmented oligodeoxy-
nucleotide (ODN) sequestration and PLT clumping upon 
addition of bacterial/viral ODNs. Collectively, this paper 
(a) tracks TLR9 to a new intracellular compartment in PLTs 
and (b) describes a novel mechanism of TLR9 organiza-
tion and signaling in human PLTs.
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Figure  1.  MKs  up-regulate  Tlr9  transcript  expression 
during pro-PLT production and express TLR9 in distinct 
granules that partially colocalize with VAMP 8 at every 
stage in thrombocytopoiesis. (A and B) Shown is a screen 
shot from Integrated Genome Browser of reads distribut-
ing to the Tlr9 (A) and Vamp8 (B) locus. The black bars 
represent piled up sequencing reads aligning to the ge-
nomic coordinates encoding the respective RNAs. More 
reads will align to more highly expressed RNA regions, 
and the height of the black bars correlates with RNA ex-
pression level. Below the read distributions are the RefSeq 
annotations: thick horizontal lines represent exons, and 
thin horizontal lines represent introns. Quantification was 
based on three round MK and four pro-PLT–MK replicates 
and is expressed in reads per kilobase of exon model per 
million mapped reads. (C) Intermediates of PLT production 
from murine fetal liver cell cultures were spun down onto 
poly-l-lysine–coated glass cover slides, permeabilized 
with 0.5% Triton X-100 for 5 min, and probed for TLR9 
and either 1-tubulin or VAMP 8. Slides were examined 
by fluorescence microscopy, and image fluorescence 
intensity is normalized to the round MK fraction. Round 
MKs, pro-PLT–MKs, released pro-PLTs, and individual PLTs 
revealed distinct, punctuate/granular localization of TLR9 
similar to that observed in whole-blood PLTs. 1-Tubulin 
antibodies were used to delineate the cell periphery and 
denote the different intermediate stages in PLT production. 
Insets (from top to bottom) represent a PLT, pre-PLT, and 
barbell pro-PLT. (D) Background fluorescence was sub-
tracted, and image brightness/contrast was adjusted lin-
early for each micrograph to resolve individual granules. 
TLR9 showed significant colocalization with VAMP 8 in 
round MKs, along the pro-PLT shafts of pro-PLT–MKs, and 
within released pro-PLTs and individual PLTs. A Manders’ 
coefficient of 0.64 was calculated for VAMP 8 colocal-
ization with TLR9 throughout the entirety of MK cell cul-
ture. Insets represent the magnified region outlined by the 
yellow box for each image.563 Platelet TLR9 localization and function • Thon et al.
TLR9 is recruited to lysosomes only after cells are stimulated 
with CpG DNA (Latz et al., 2004). The fact that all intracellu-
lar TLRs identified share specificity for nucleic acids suggests 
that this localization may be related to the recognition of this 
class of ligand (Barton et al., 2006). Synthetic oligodeoxynu-
cleotides (ODNs) that contain unmethylated CpG motifs are 
typically used to activate TLR9. Type C CpG motifs contain   
a complete phosphorothioate backbone and a CpG-containing 
palindromic motif that is present at a 20-fold greater fre-
quency in bacterial DNA compared with mammalian DNA 
(Bauer et al., 2001). Although type C CpG ODNs induce 
strong IFN- production from both plasmacytoid dendritic 
cells and B cells, the effect of TLR9 signaling in PLTs re-
mains to be established.
In this paper, we use confocal and electron microscopy 
to track TLR9 during pro-PLT production to a new electron-
dense tubular system-related compartment in PLTs. Second, 
we use known PLT agonists to describe a novel mechanism 
of TLR9 signaling whereby PLTs are primed during activa-
tion to express TLR9 on their surface before secondary activa-
tion through pathogen-associated molecular patterns (PAMPs) 
on invading organisms. Finally, we reveal a unique role for 
human PLTs as mediators of innate immunity at sites of vas-
cular damage.
Results
TLR9 is expressed in murine cell culture 
megakaryocytes (MKs) and is distributed 
to PLTs during pro-PLT production
Because TLR9 is a transmembrane receptor, we hypothesized 
that TLR9 should be translated by bone marrow MKs and 
transported  along  pro-PLT  extensions  to  nascent  PLTs.  To 
test this hypothesis, mouse fetal liver cell cultures were gen-
erated, and round MKs, pro-PLT–producing MKs, released 
pro-PLTs,  and  individual  PLTs  were  isolated  on  day  5  of 
culture. Next generation RNA sequencing of round MKs and 
pro-PLT–MKs confirmed the presence of the Tlr9 and Vamp8 
transcripts in murine cell cultures (Fig. 1, A and B). Com-
parison of Tlr9 expression profiles between the two revealed 
that MKs experience a burst of Tlr9 mRNA expression dur-
ing pro-PLT production (0.34 ± 0.21 vs. 2.44 ± 0.75 RPKM,   
n ≥ 3). Pro-PLT–producing MKs did not experience a similar 
burst of Vamp8 mRNA expression during pro-PLT produc-
tion, which was used as an internal control (70.9 ± 14.5 vs. 
60.4 ± 3.2 RPKM, n ≥ 3). These results confirm that TLR9 is 
generated by MKs during pro-PLT production. Intermediates 
in PLT production were probed for TLR9 and 1-tubulin to 
delineate the cell periphery, and samples were visualized by 
immunofluorescence microscopy (Fig. 1 C). TLR9 was pres-
ent in mouse MKs, pro-PLT–MKs, released pro-PLTs, and in-
dividual PLTs and showed punctate/granular expression that 
partly colocalized with VAMP 8 at each stage of PLT produc-
tion (Fig. 1 D). SNAREs, such as VAMP 8, associate with PLT 
granules and may mediate TLR9 localization to nascent PLT 
tips during thrombocytopoiesis.
Human PLTs sequester TLR9 and  
protein disulfide isomerase (PDI) in 
previously undescribed electron-dense 
tubular system-related T granules
To  confirm  that  the  majority  of  TLR9  in  resting  PLTs  is   
expressed intracellularly, washed PLTs were spun down onto 
poly-l-lysine–coated glass cover slides, permeabilized, and 
probed for either TLR9 (Fig. 2 A, green) alone or TLR9 (Fig. 2 B,   
green)  and  1-tubulin  (Fig.  2  B,  red)  together.  Immuno-
fluorescence microscopy revealed that both human (Fig. 2 A)   
and mouse (Fig. S1) whole-blood PLTs demonstrate punctu-
ate/granular expression of TLR9 mostly (69 ± 5%) along the 
cell periphery, adjacent to the plasma membrane. TLR9 local-
ization to the cell edge was confirmed in human PLTs by co-
labeling with 1-tubulin to demarcate the PLT border (Fig. 2 B).   
Unlike TLRs 1–6, which are always expressed on the cell 
surface, TLR9 is typically expressed in macrophage or mast cell 
endosomes. Interestingly, TLR9 was shown not to colocalize   
Figure 2.  Human PLTs express TLR9 in distinct granules along the pe-
riphery of the cell, adjacent to the plasma membrane. (A and B) Washed 
human whole-blood PLTs were spun down onto poly-l-lysine–coated glass 
cover slides, permeabilized with 0.5% Triton X-100 for 5 min, and were 
probed for either TLR9 alone or TLR9 and 1-tubulin together. (A) Samples 
were examined by wide-field fluorescence microscopy and revealed pe-
ripheral labeling of TLR9 in distinct, punctate granules that localized mostly 
(69 ± 5%) along the cell periphery, adjacent to the plasma membrane.   
(B) TLR9 localization to the cell edge was confirmed in human PLTs by 
colabeling with 1-tubulin to demarcate the PLT border. Inset represents 
magnified region outlined by the yellow box. (inset) Bar, 5 µm.JCB • VOLUME 198 • NUMBER 4 • 2012   564
Videos 1 and 2). Representative maximum projection z series 
for TLR9 and PDI (Fig. 4 A) confirmed that TLR9 is distribut-
ing with PDI to a separate granular compartment.
To surpass the resolution limit of conventional fluores-
cence microscopy (200 nm) and because Gray PLT syndrome 
PLTs express some -granule membrane proteins in normal 
amounts (Rosa et al., 1987; Maynard et al., 2010), TLR9 and 
PDI localization was examined by immunogold electron micros-
copy. PLT cryosections were probed for TLR9 (Fig. 4 B) and 
PDI (Fig. 4 C) separately and together (Fig. 4, D and E). TLR9 
distributed to previously uncharacterized electron-dense granu-
lar compartments to which PDI was also shown to colocalize 
(Fig.  4,  B–D). These  were  named T  granules  after TLR9 
electron-dense tubular system-related granular compartments. 
TLR9/PDI labeling was associated with the limiting membrane, 
and T-granule identification was based on the colocalization of 
three or more immunogold molecules within a single electron-
dense area (Fig. 4 B–E, denoted by white arrows). T granules had 
with  known  specific  markers  of    granules  (fibrinogen, 
CD62P, PDGF-B, VEGF, CD42a, and CD42b), dense granule 
(serotonin), lysosome (LAMP-1), or endosome (M6P and Syn-
taxin-13) protein markers (Fig. 3 A). To validate this observa-
tion, TLR9 labeling of whole-blood PLTs from human normal 
controls  was  compared  with  Gray  PLT  and  Hermansky– 
Pudlack syndrome patients, which are devoid of -granule 
and dense-granule content, respectively (Fig. 3 B). Punctate/
granular expression of TLR9 in these samples was undimin-
ished and suggests that TLR9 is not contained in PLT  or 
dense granules.
In professional dendritic cells, TLR9 is distributed to in-
tracellular endosomal compartments along with TLR7 and TLR8. 
PDI, by comparison, is highly expressed in the endoplasmic   
reticulum of endothelial cells and electron-dense tubular system-
related compartments in PLTs (van Nispen Tot Pannerden   
et al., 2009). Interestingly, although PDI colocalized with TLR9 
in resting human PLTs, TLR7 and TLR8 did not (Fig. 3 C and 
Figure 3.  TLR9 does not colocalize with known PLT  granule, dense granule, lysosomal, or endosomal markers. Washed human whole-blood PLTs were 
spun down onto poly-l-lysine–coated glass cover slides, permeabilized with 0.5% Triton X-100 for 5 min, and probed for TLR9. (A) PLTs were colabeled for 
 granule (fibrinogen, CD62P, PDGF-B, VEGF, CD42a, and CD42b), dense granule (serotonin), lysosome (LAMP-1), or endosome (M6P and syntaxin-13) 
protein markers using two separate colors. Insets represent magnified regions outlined by the yellow boxes for each image. (B) TLR9 labeling of whole-
blood PLTs from patients with Gray PLT and Hermansky–Pudlack syndromes was compared with human normal PLT controls. All samples were examined 
by wide-field fluorescence microscopy. (C) 2D intensity scatter plot analysis of image overlays reveal that, although TLR9 colocalizes well with PDI, it does 
not colocalize with either TLR7 or TLR8. These data suggest that TLR9 and PDI may be distributing to a unique intracellular body (T granule) underlying the 
plasma membrane in resting human PLTs. (insets) Bars, 2 µm.565 Platelet TLR9 localization and function • Thon et al.
immunofluorescence  microscopy,  and  both  risk  ratio  and 
Manders’ coefficients were calculated for each association. Rep-
resentative figures are shown in Fig. 5, and results for colocal-
izations are summarized in Table 1. TLR9 did not associate with 
VAMPs 2 and 3 (not depicted) and shows poor association with 
VAMP 5, which was included as an internal threshold control 
(Fig. 5 A). Manders’ coefficients of 0.5 or greater were consid-
ered significant, and TLR9 showed partial colocalization with 
both VAMPs 7 and 8 in resting PLTs (Fig. 5, B and C). After 
PLT activation (spreading) on glass, VAMP 8 was redistributed 
to the PLT granulomere, whereas VAMPs 5 and 7 distributed to 
the PLT lamellipodium. TLR9 continued to show colocalization 
with VAMP 8 after spreading, which demonstrates that there 
are two major subpopulations of T granules in PLTs that can 
a mean cross-sectional area of 4,148 nm
2, and there were a mean   
of eight T granules per PLT cross-sectional area (1,750,019 nm
2)   
in 25 PLTs analyzed.
T-granule localization/plasma membrane 
fusion accompanies VAMP 7 and 8 
reorganization on PLT activation
Because SNAREs mediate -granule localization in PLTs, we 
hypothesized that these might also colocalize with T-granule 
reorganization  during  PLT  activation  and  plasma  membrane 
fusion. SNAREs are divided into t-SNAREs and v-SNAREs, 
which in PLTs include VAMPs 2, 3, 5, 7, and 8 (Graham et al., 
2009). v-SNARE colocalization with TLR9 in resting and 
thrombin-activated human PLTs was determined by confocal   
Figure 4.  TLR9 colocalizes with PDI to electron-dense membrane-encapsulated regions adjacent the plasma membrane along the periphery of human PLTs. 
(A) Representative maximum projection z series for TLR9 and PDI by confocal immunofluorescence microscopy demonstrating colocalization. (B–E) Washed 
human whole-blood PLTs were fixed, frozen, and sectioned before mounting on Formvar carbon-coated copper grids. Ultrathin PLT sections were probed for 
TLR9, and bound antibody was labeled with immunogold. Samples were examined by electron microscopy and reveal the distribution of TLR9 (B), PDI (C), 
and colocalization of both (D and E) along the periphery of resting human PLTs. White arrows denote localization of TLR9 and PDI to limiting membrane of 
electron-dense regions adjacent the plasma membrane. (D and E) For colabeling, immunogold particles are 15 nm for PDI and 10 nm for TLR9.JCB • VOLUME 198 • NUMBER 4 • 2012   566
Figure  5.  Human  PLT  TLR9  localization  with 
VAMPs 5, 7, and 8 under resting conditions and 
when activated (spread) on glass surface. Sam-
ples were examined by confocal fluorescence 
microscopy. Image analysis was completed by 
using  the  JACoP  (Just  Another  Colocalization 
Plugin) plugin for ImageJ as described in Table 1.   
Manders’  coefficients  were  used  to  compare 
the TLR9 relationship to the associated VAMP. 
(A) Micrographs demonstrating the relationship 
of VAMP 5 and TLR9. As demonstrated in the 
micrographs, in the resting PLT, 41% of TLR9 
signal overlaps with that of VAMP 5. The por-
tion of overlapping signal slightly increased in 
the adhered PLTs to 49%. (B) Additional micro-
graphs demonstrating the relationship between 
VAMP  7  and  TLR9.  Image  analysis  confirms 
82% of TLR9 overlapped with that of VAMP 7 
in the resting PLT; however, upon spreading, the 
signal decreased to only 56%. (C) Micrographs 
of resting and spread PLTs probed with specific 
antiserum for VAMP 8 and TLR9. In the rest-
ing PLT, 77% of TLR9 signal overlapped with 
VAMP 8. Upon spreading, the signal decreased 
to 67% signal overlap.567 Platelet TLR9 localization and function • Thon et al.
be differentially distributed on PLT activation. Localization of 
VAMPs to the PLT granulomere or lamellipodium on contact 
activation has been associated with granule membrane fusion 
with the plasma membrane or the open canalicular system, 
respectively (Flaumenhaft, 2003), and accounts for TLR9 sur-
face expression.
TLR9 is expressed on the PLT surface 
during activation
Unlike TLRs 1–6, TLR9 is exclusively expressed intracellu-
larly in the professional dendritic cells (Barton et al., 2006). 
To  determine  whether  PLTs  express  TLR9  on  the  plasma 
membrane  under  resting  conditions  and  whether  activation 
with a strong PLT agonist will cause TLR9 to relocate to the 
PLT surface, human PLTs were collected from whole blood 
and incubated with thrombin. Thrombin is a key regulator of 
the coagulation cascade and activates PLTs through the protease-
activated receptors 1 and 4 in humans. Flow cytometry and 
immunofluorescence  microscopy  were  used  to  measure  the 
surface expression of TLR9 in human PLTs under resting con-
ditions and after PLT activation (Fig. S3). Surprisingly, resting 
PLTs expressed basal levels of surface TLR9 that became sig-
nificantly increased after thrombin activation, suggesting that 
although the majority of TLR9 is expressed intracellularly, 
some of it relocates to the plasma membrane on agonist expo-
sure. Although it is unknown what local concentrations of 
bacterial DNA are achieved in vivo, increased TLR9 surface 
expression in thrombin-activated PLTs corresponded with in-
creased surface binding of the synthetic TLR9 ligand, unmeth-
ylated CpG ODN, when ≥5 µM, and was therefore used at this 
concentration for all subsequent experiments (Fig. S3 A and 
Fig. S5). TLR9 surface expression was also regulated by PLT 
activation through other common PLT agonists that stimulate 
PLT activation and granule release through separate signaling 
pathways. These included ADP and type IV collagen, which 
were chosen because they represent well characterized, physi-
ologically relevant agonists, PMA, which is a potent secreta-
gogue used in both PLTs and leukocytes to evaluate granule 
exocytosis,  and  the  GPVI  agonist  collagen-related  peptide 
(CRP), given the importance of the GPVI receptor in PLT 
function. These data demonstrate that human PLTs may need 
to be primed to respond to bacterial/viral PAMPs in whole 
blood (Fig. 6). Moreover, although the direct addition of type 
IV collagen to resting PLTs resulted in much higher levels of 
TLR9 surface expression than did thrombin, these results were 
not matched with a significant increase in CD62P surface   
expression and revealed lower levels of CD61 surface ex-
pression relative to CRP controls, confirming that TLR9 and 
CD62P/CD61  localize  to  separate  organelles.  Conversely, 
CRP-mediated PLT activation resulted in significantly higher 
levels of both CD62P and CD61 surface expression than did 
type IV collagen but were met with relatively lower levels of 
TLR9 surface expression, as confirmed by quantitative immuno-
fluorescence microscopy (Fig. S4).
TLR9 regulates DNA sequestration and 
CD62P surface expression in PLTs
Unmethylated ODNs, including a CpG motif, can mimic the 
effects of bacterial DNA, inducing B cell proliferation and   
activating cells of the myeloid lineage. We hypothesized that 
the addition of type C CpG to washed human PLTs may induce 
PLT activation and possibly result in increased surface expres-
sion of TLR9 and CD62P and ODN sequestration. Although 
incubation of resting human PLTs with synthetic unmethylated 
type C CpG did not cause PLT shape change (Fig. S2), it did 
result in a 37 ± 13% increase in TLR9 and 34 ± 15% increase 
in CD62P surface expression followed by a 31 ± 15% increase 
in FITC-conjugated type C CpG sequestration over 20 min   
(Fig. 7, A and C). Surprisingly, when TLR9 surface expression 
was specifically up-regulated by preincubating PLTs with type IV 
collagen, subsequent incubation with type C CpG resulted 
in 100% of PLTs demonstrating increased type C CpG seques-
tration, CD62P surface expression, and PLT clumping within   
30 s of addition (Fig. 7, B and C; and Videos 3 and 4). This was 
inhibited by preincubating the PLT culture with 20 µM IRAK-1/4   
(interleukin-1  receptor-associated  kinase-1/4  inhibitor)  for 
1 h before collagen IV incubation and type C CpG addition   
(Videos 3 and 4). IRAK-1 and IRAK-4 are protein kinases that   
mediate signaling by TIR (Toll/IL1/Plant R) domain–containing 
receptors, including the IL-1, IL-8, and TLRs (Song et al., 
2009). Pharmacological inhibition of both kinases blocked PLT 
clumping by type C CpG in the presence of type IV collagen 
and reveals downstream signaling effectors of ODN-mediated 
PLT activation.
Unlike in human PLTs that contain 0.5 RPKM TLR9 
RNA, TLR9 surface expression was not changed in mice after 
type C CpG incubation, and deep sequencing of mouse PLTs 
has shown that they do not contain detectable levels of TLR9 
RNA  (Rowley  et  al.,  2011).  Interestingly,  although  preincu-
bation with type IV collagen still resulted in immediate PLT 
clumping when type C CpG was added (unpublished data), 
TLR9  knockout  (KO)  mice  show  reduced  levels  of  ODN   
Table 1.  Calculated risk ratio and Manders’ coefficients for each association of TLR9 with VAMPs 5, 7, and 8
Colocalization with 
TLR9
Resting Spread (glass)
  Rr M1 TLR9/VAMP M2 VAMP/TLR9 Rr M1 TLR9/VAMP M2 VAMP/TLR9
VAMP 5 0.7 ± 0.1 0.4 ± 0.2 0.4 ± 0.2 0.5 ± 0.1 0.5 ± 0.2 0.14 ± 0.04
VAMP 7 0.84 ± 0.02 0.82 ± 0.08 0.4 ± 0.1 0.69 ± 0.09 0.56 ± 0.08 0.32 ± 0.09
VAMP 8 0.50 ± 0.03 0.77 ± 0.02 0.59 ± 0.02 0.4 ± 0.1 0.68 ± 0.04 0.4 ± 0.2
Calculated risk ratio (Rr) and Manders’ coefficients for each association of TLR9 with VAMPs 5, 7, and 8 in human whole-blood PLTs under resting conditions and 
when activated (spread) on glass surface. Manders’ coefficients of 0.5 or greater were considered significant and are highlighted in bold.JCB • VOLUME 198 • NUMBER 4 • 2012   568
regard to TLR9 binding (specificity control), resting/thrombin- 
activated human PLTs were incubated with 5 µM FITC-conjugated   
type  C  CpG  and  decreasing  concentrations  of  unlabeled 
sequestration and CD62P surface expression relative to isotype-
matched wild-type controls. To confirm that FITC-conjugated 
type C CpG behaves like nonconjugated type C CpG with   
Figure  6.  Human PLTs regulate surface ex-
pression of TLR9 on activation with select ago-
nists. Human PLTs were collected from whole 
blood and examined under resting conditions 
or after activation with 1 mU/µl thrombin, 1 µM 
PMA, 3 µg/ml CRP, 20 µM ADP, or 50 µg/ml 
mouse type IV collagen for 5 min at 37°C. 
Samples  were  probed  for  TLR9  and  either 
CD62P or CD61. PLT mean fluorescence inten-
sity (relative surface expression of targeted re-
ceptor) was determined by flow cytometry for 
at least three different samples, and data were 
subject to one-way ANOVA and Tukey HSD 
analysis.  Error  bars  represent  one  standard 
deviation about the mean for at least three in-
dependent samples. (A) Human PLT activation 
with all listed agonists results in increased sur-
face expression of TLR9 relative to resting con-
trol. Strikingly, TLR9 surface expression on PLT 
activation did not correlate with CD62P/CD61 
expression for the agonists tested and suggests 
that TLR9 and CD62P/CD61 may localize to 
separate granules. (B, left) Representative for-
ward scatter versus side scatter dot plots high-
light characteristic changes in PLT morphology 
on activation with the listed agonists relative 
to  resting  control.  (right)  Representative  his-
tograms demonstrate a shift in mean fluores-
cence intensity for TLR9 and CD62P/CD61 
on PLT activation. Outlines represent PLT gate 
used for sample thresholding by forward and 
side  scatter.  Mean  fluorescence  intensity  for 
resting PLTs is represented in gray. Mean fluor-
escence intensity for agonist-activated PLTs is 
represented in red.569 Platelet TLR9 localization and function • Thon et al.
tested. To determine whether circulating ODNs also result in 
increased  thrombus  formation,  washed  human  whole-blood 
PLTs and PLT-rich plasma (PRP) were pretreated with 5 µM 
control ODN, type C CpG ODN, or a vehicle control and per-
fused at a shear rate of 200 s
1 (flow rate of 18.7 µl/min) over 
a surface coated with type IV collagen or type I collagen for 
(cold) type C CpG and analyzed by flow cytometry (Fig. S5). 
Thrombin-activated PLTs showed fluorescence profiles that   
correlated  exactly  with  the  relative  proportion  of  FITC-
conjugated type C CpG in the culture. Resting human PLTs 
showed fluorescence profiles that were comparable with the 
20-µM unlabeled type C CpG control at all the concentrations 
Figure 7.  TLR9 signaling results in type C CpG sequestration, increased CD62P surface expression, and PLT clumping. (A and B) Flow cytometric analysis 
showing representative forward versus side scatter profiles of human washed PLTs under resting conditions and after incubation with synthetic unmethylated 
type C CpG ODNs (characteristic of bacterial/viral DNA) before (A) and after (B) type IV collagen preincubation. Outlines represent PLT gate used for 
sample thresholding by forward and side scatter. (C) Quantification of the percentage of PLTs expressing TLR9, CD62P, and type C CpG was normalized 
to resting levels to resolve the difference on agonist exposure over time. Incubation of resting washed human PLTs with type C CpG ODNs resulted in a 
40% increase in TLR9 surface expression followed by a 30% increased type C CpG sequestration and CD62P surface expression over 20 min. (D) Type IV 
collagen preincubation resulted in considerably increased type C CpG sequestration, CD62P surface expression above resting PLT controls, and significant 
PLT clumping within 30 s of type C CpG addition. (E) Mouse PLTs show a more pronounced ODN sequestration and comparable CD62P expression after 
type C CpG incubation. Unlike in human PLTs, TLR9 surface expression is not changed in mice. Although TLR9 KO mice show reduced levels of ODN 
sequestration and CD62P surface expression 20 min after type C CpG addition, preincubation with type IV collagen still resulted in immediate PLT clump-
ing when type C CpG was added (not depicted). Statistical significance for marked pairings was established using a one-tailed Student’s t test for paired 
samples (*, P < 0.05; **, P < 0.01). Error bars represent one standard deviation about the mean.JCB • VOLUME 198 • NUMBER 4 • 2012   570
(Fig. 8, A and B), these did not form thrombi as compared with 
type I collagen (Fig. 8 C). Addition of type C CpG did not result 
in increased thrombus formation relative to the ODN control   
in PRP on the type I collagen-coated surface.
In monocytes, macrophages, and plasmacytoid dendritic 
cells, TLR9 localizes to intracellular membranes, such as those 
of endosomes or phagosomes (Hennessy et al., 2010). This 
permits TLR9 to respond to nucleic acids from bacterium/ 
virus  that  have  been  endocytosed/phagocytosed  by  the  cell, 
while preventing recognition of self-DNA (Barton et al., 2006). 
To test whether this is the case in human PLTs, samples were 
incubated with FITC-conjugated type C CpG at 37°C and 5% 
CO2 for a period of ≤4 h. PLTs were subsequently spun down 
onto  poly-l-lysine–coated  glass  cover  slides  and  probed  for 
TLR9 as described in the Immunofluorescence microscopy 
section of Materials and methods. Fig. 8 (D and E) shows that 
within the first hour of incubation the majority of type C CpG 
was sequestered to the PLT surface. Although prolonged exposure 
of human PLTs to FITC–type C CpG (4 h) induced endocytosis 
of the ODN, these showed minimal colocalization with intra-
cellular PLT TLR9.
Discussion
Here, we show that TLR9 mRNA is expressed by mature MKs 
and becomes specifically up-regulated during pro-PLT pro-
duction. Differential mRNA expression has previously been 
shown for TIMP-3 (Cecchetti et al., 2011) and suggests that 
TLR9 mRNA is selectively withheld or rapidly degraded in 
circulating PLTs. We speculate that increased TLR9 protein 
translation at this stage is necessary to package TLR9 pro-
tein into newly generated PLTs. VAMP 8 colocalizes with 
TLR9 protein throughout pro-PLT maturation and may be 
responsible for distributing T granules to PLT-sized swell-
ings, where it is distributed with PDI to unique electron-dense 
membrane-delimited intracellular compartments we have named 
T granules. Localization of PDI to T granules suggests they 
may be derived from the endoplasmic reticulum of MKs and 
therefore related to the dense tubular system in PLTs (White 
and Gerrard, 1976). PDI facilitates the formation of disulfide 
bonds and proper folding of newly synthesized proteins. Se-
cretion and targeting of PDI to the surface of activated PLTs 
is thought to contribute to isomerase activity, affect adhesion 
to CD41/61, 2-1, and GPIb, and regulate the procoagulant 
activity of tissue factor (Chen et al., 1992, 1995; Essex et al., 
1995; Burgess et al., 2000; Lahav et al., 2003; Ahamed et al., 
2006). T granules can be organized in two major subpopu-
lations that differentially associate with either VAMP 7 or 
VAMP 8. Although thought to reside exclusively in the en-
dosomes of monocytes, macrophages, and plasmacytoid den-
dritic cells, TLR9 surface expression is significantly increased 
in PLTs after incubation with thrombin, ADP, PMA, CRP,   
and type IV collagen, demonstrating partial activation-mediated 
granule release. SNAREs represent the core of the fusion   
machinery, and the distribution and association of v-SNAREs, 
such as VAMP 8, with t-SNAREs provides the basis for -granule   
localization  and  secretion  (Blair  and  Flaumenhaft,  2009).   
10  min  (Fig.  8, A–C;  and Videos  5–11). Although  addition 
of ODN to PLTs in the presence of type IV collagen resulted 
in PLT clumping and adhesion to the flow chamber surface   
Figure 8.  ODN-activated PLTs do not form thrombi on collagen type IV 
and endocytose type C CpG to distinct granules that do not colocalize   
with TLR9. (A–C) Washed human whole-blood PLTs (A) and PRP (B) were 
pretreated with 5 µM control ODN, type C CpG ODN, or a vehicle control 
and perfused at a shear rate of 200 s
1 (flow rate of 18.7 µl/min) over 
a surface coated with type IV collagen or type I collagen (C) for 10 min. 
Although addition of ODN to PLTs resulted in PLT clumping in the presence 
of type IV collagen (white arrows), these did not form thrombi as compared 
with type I collagen (positive control, black arrows). Addition of type C 
CpG did not result in increased thrombus formation relative to the ODN 
control in PRP on the type I collagen-coated surface. (D) PLTs were incu-
bated with FITC-conjugated type C CpG at 37°C and 5% CO2 for a period 
of ≤4 h. PLTs were subsequently spun down onto poly-l-lysine–coated glass 
cover slides and probed for TLR9. After 1 h of incubation, the majority 
of FITC-conjugated type C CpG was associated with the PLT surface and 
did not colocalize with TLR9. (E) Samples were examined by wide-field 
fluorescence microscopy. After 4 h of incubation, FITC-conjugated type 
C CpG became endocytosed by resting human PLTs into distinct granules 
that showed minimal colocalization with TLR9. Insets represent (from left to 
right) type C CpG labeling, TLR9 labeling, and colabeling of magnified 
region outlined by the yellow boxes in the images. (insets) Bars, 2 µm.571 Platelet TLR9 localization and function • Thon et al.
KO mouse PLTs still aggregated when type C CpG was added 
after preincubation with type IV collagen, which substantiates 
the  previously  reported  prevalence  of  non-TLR9–mediated   
effects of CpG. Indeed, although the absence of CpG recog-
nition by TLR9 significantly reduces acute inflammatory re-
sponses to systematically delivered cationic lipid–plasmid DNA 
complexes, it does not eliminate them, and TLR9 KO mice still 
exhibit  a  pronounced  loss  of  lymphocytes  and  PLTs  (Zhao   
et al., 2004). Collectively, these findings suggest that signaling 
through TLR9 does not exclusively contribute to PLT activa-
tion when exposed to bacterial/viral DNA and predict the pres-
ence of at least one other yet-uncharacterized receptor of CpG 
on the PLT surface. Even so, increased surface expression of 
TLR9 in human PLTs, and type C CpG sequestration may help 
regulate circulating levels of bacterial DNA in whole blood and 
thus control the inflammatory response after bacterial cell lysis. 
The interaction of bacteria with human PLTs plays an important 
role in the pathogenesis of cardiovascular infection, and serious 
complications of bacteremia include life-threatening infective 
endocarditis, disseminated intravascular coagulation, immune 
thrombocytopenia purpura, and increased risk of myocardial 
infarction (Fitzgerald et al., 2006). A better understanding of 
the role TLRs play in regulating PLT activation will lead to 
targeted therapies for treating and preventing serious cardiovas-
cular infections. Moreover, the development of small molecule 
inhibitors of PLT interactions with specific bacterial compo-
nents have the advantage of bypassing present antibiotic resis-
tance mechanisms and may be ideal for prophylaxis of infection 
in susceptible individuals. (Fitzgerald et al., 2006).
Materials and methods
Human/murine whole-blood PLTs
Human blood was obtained by venipuncture from healthy laboratory volun-
teers, a Gray PLT syndrome patient, and a Hermansky–Pudlack syndrome 
patient as previously described (Hartwig and DeSisto, 1991). Collections 
were performed in accordance with ethics regulation with International 
Review Board approval, and informed consent was provided according 
to the Declaration of Helsinki. Murine blood was obtained by retro orbital 
bleed into 0.1 vol Aster–Jandl anticoagulant from anesthetized mice as 
previously described (Hoffmeister et al., 2003). Gray PLT syndrome patient 
whole blood was provided by A. Michelson (Harvard Medical School, 
Boston, MA). Hermansky–Pudlack syndrome patient whole blood was pro-
vided by R. Flaumenhaft (Harvard Medical School, Boston, MA). TLR9 KO 
mice were provided by D. Golenbock and B. Caetano (University of Mas-
sachusetts Medical School, Worcester, MA).
MK suspension cultures
Mouse fetal liver cells were collected from wild-type CD1 mice (Charles 
River) on embryonic day 13.5 and cultured at 37°C and 5% CO2 in the 
presence of 0.1 µg/ml purified recombinant mouse c-Mpl ligand for 5 d.   
Round MKs, pro-PLT–MKs, and released pro-PLTs were isolated by BSA 
gradient sedimentation and cultured separately as previously described 
(Thon et al., 2010). In brief, fetal liver cell cultures were layered on a 
single-step gradient (1.5–3.0% BSA) on culture day 4, and MKs were 
allowed to sediment for 30 min. The MK pellet was then resuspended 
in fresh media and cultured for an additional 24 h during which pro-PLT 
production was readily observed and layered on a second single-step 
gradient (1.5–3.0% BSA) on culture day 5. MKs were allowed to sedi-
ment for 30 min, and MKs were isolated from the pelleted fraction, pro-
PLT–producing MKs were isolated from the BSA fraction, and released 
pro-PLTs and PLTs were isolated from the upper (culture media) fraction. 
Preparation of polyadenylated RNA for sequencing on the Genome Analyzer 
IIx (Illumina) followed by alignment and analysis was performed as previ-
ously described (Rowley et al., 2011). In brief, cells were lysed in TRIZOL 
Because TLR9 partly redistributes to the plasma membrane 
on contact activation with glass, T-granule colocalization with 
VAMP 8 and reposition to the PLT granulomere in spread 
PLTs suggest that increased TLR9 surface expression occurs 
through VAMP 8–mediated T-granule fusion with the open 
canalicular system (Flaumenhaft, 2003).
TLRs  functionally  modulate  innate  immunity  by  rec-
ognizing PAMPs on invading microorganisms (Hemmi et al., 
2000). This is particularly true of bacterial/viral DNA, which 
depend  on  the  presence  of  unmethylated  CpG  ODNs.  By 
comparison, mammalian DNA has a lower frequency of CpG 
ODNs, is methylated, and does not have immune-stimulatory 
activity (Krieg, 1996; Lipford et al., 1998; Yamamoto et al., 
2000). TLR9 has been identified as the receptor involved in the 
recognition of immunostimulatory CpG motifs (Hemmi et al., 
2000; Bauer et al., 2001) and is uniquely expressed in periph-
eral granules in resting PLTs and on the human PLT surface 
after  activation.  Immunostimulatory  CpG  motifs  have  been 
implicated as a major contributor to the acute inflammatory 
response associated with nonviral vectors, most prominently 
seen after systemic delivery of cationic lipid–plasmid DNA 
complexes (Zhao et al., 2004). Unmethylated CpGs have been 
shown to stimulate B cell proliferation and macrophage activa-
tion and induce dendritic cell maturation (Krieg et al., 1995; 
Stacey et al., 1996; Sparwasser et al., 1998). Incubation of 
resting PLTs with synthetic unmethylated type C CpG ODNs 
(characteristic  of  bacterial/viral  DNA)  resulted  in  increased 
surface expression of TLR9 in humans and increased CD62P 
surface expression and type C CpG sequestration over 20 min 
in both humans and mice. Indeed, TLR9 KO mice sequester 
50% less type C CpG and have significantly reduced levels 
of CD62P surface expression relative to isotype-matched wild-
type controls.
Upon  vascular  damage,  PLTs  are  recruited  to  the  site   
of injury where they adhere to exposed basement membrane, 
become activated, and contribute to clot formation. The basement 
membrane is particularly rich in type IV collagen and PLT   
recruitment to a site of vascular injury may serve to sensitize the 
PLT to bacteria/virus DNA. Interestingly, when TLR9 surface 
expression was specifically increased by preincubating PLTs 
with type IV collagen, subsequent incubation with type C CpG 
resulted in considerably enhanced type C CpG sequestration, 
CD62P surface expression, and PLT clumping within 30 s of 
addition but did not result in thrombi formation. These results 
imply that PLTs must be primed to express TLR9 on their sur-
face  before  signal  transduction  through  TLR9  and  provide   
a mechanism for PLT regulation of the immune response to   
infection in human whole blood by sequestering bacterial/viral 
DNA and marking themselves for clearance.
Interestingly, mouse PLTs did not show increased surface 
expression of TLR9 on addition of the ODN. Indeed, human 
PLTs express several surface receptors absent in mice (e.g., 
PAR1). With regard to TLR expression, human myeloid den-
dritic cells express functional TLR8, whereas mice do not. Con-
versely, although both myeloid and plasmacytoid dendritic cells 
in mice express intracellular TLR7 and TLR9, these are not 
present in human myeloid dendritic cells. Nevertheless, TLR9 JCB • VOLUME 198 • NUMBER 4 • 2012   572
oil immersion objective, and images were obtained using a charged-coupled 
device (CCD) camera (ORCA-ER; Hamamatsu Photonics). Images were ana-
lyzed using the MetaMorph image analysis software (Molecular Devices) and 
ImageJ (National Institutes of Health).
For colocalization experiments with PDI, TLRs 7 and 8, and VAMPs   
5,  7,  and  8,  4.0  ×  10
6  washed  PLTs  were  spun  down  onto  poly-l- 
lysine–coated cover slides in either 4% formaldehyde (resting PLTs) or in 
PLT resuspension buffer (10 mM Hepes, 140 mM NaCl, 3 mM KCl, 0.5 mM 
MgCl2, 5 mM NaHCO3, and 10 mM glucose, pH 7.4) and allowed to 
spread on a glass slide for 15 min at room temperature before fixation 
(spread PLTs). Samples were permeabilized with 0.5% Triton X-100 and 
blocked in immunofluorescence blocking buffer overnight before antibody 
labeling and then incubated with IgG matching the primary antibody’s 
species to block nonspecific binding. PLTs were subsequently probed with 
primary antibodies against TLR9 (Imgenex) and PDI (Abcam), TLR7 (Abcam),   
TLR8 (Abcam), VAMP 5 (Abcam), VAMP 7 (SYBL1; Abcam), or VAMP 8 
(Synaptic Systems). Fluorescence images were visualized using a confo-
cal microscope (BX62; Olympus) equipped with a 60×, NA 1.42 Plan-
Apochromat oil immersion objective and captured with a cooled CCD 
camera (ORCA-ER). Image acquisitions were controlled by iVision-Mac 
(BioVision Technologies). Additional images were acquired by a confo-
cal laser-scanning microscope with a TCS SP2 (for PDI, TLR7, and TLR8; 
Leica) or LSM 510 Meta system (for VAMPs 5, 7, and 8; Carl Zeiss). 
Fluorescence images of two colors were captured sequentially using laser 
lines at 488 nm (for Alexa Fluor 488) and 561 nm (for Alexa Fluor 568). 
Series of x-y images were collected along the z axis at 0.244-µm intervals 
using a Plan-Apochromat 63×, NA 1.4 oil immersion objective using an 
optical zoom of 2×. Image analysis and colocalization values were gen-
erated using ImageJ and Volocity (PerkinElmer) software. For PDI, TLR7, 
and TLR8 colocalization experiments, three individual images were aver-
aged to generate a representative image for each sample plane. At least 
11 averaged images were collected at 0.244-µm steps along the z axis 
of each sample for both fluorescence channels, and Pearson’s correla-
tion coefficients above threshold were calculated using the Colocalization 
Threshold macro written by T. Collins and W. Rasband (National Institutes 
of Health, Bethesda, MD) for ImageJ.
Immunogold electron microscopy
Rapid-freeze immunogold electron microscopy of washed human PLTs was 
performed as previously described (Italiano et al., 1999). In brief, human 
PLTs were fixed with 1.25% paraformaldehyde, 0.03% picric acid, and 
2.5% glutaraldehyde in 0.1 M cacodylate buffer, pH 7.4. Ultrathin sections 
were probed for TLR9 (Imgenex) and labeled with protein A–gold (British 
Biocell International) before staining/embedding. Grids were examined 
with an electron microscope (G2 Spirit BioTwin; Tecnai) at an accelerating 
voltage of 80 kV. Images were recorded with an Advanced Microscopy 
Techniques 2k CCD camera using Advanced Microscopy Techniques digital 
acquisition and analysis software.
Differential interference contrast live-cell imaging of PLT clumping
Washed human PLTs were transferred onto video chambers maintained 
at 37°C. Cells were viewed on an inverted microscope (TE-200; Nikon) 
equipped with a 63× oil immersion objective, and images were obtained 
using a CCD camera (ORCA-ER). Videos were prepared using the Meta-
Morph software package and ImageJ. Pictures of PLTs cultured with either 
20 µM IRAK-1/4 for 1 h or a vehicle control and 50 µg/ml type IV col-
lagen were captured at 30-s intervals over a course of 20 min. 5 µM type C   
CpG was then added to the PLT culture, and images were captured   
for an additional 20 min. Experiments were performed for at least three 
different samples.
Perfusion analysis of PLT thrombus formation
Washed human whole-blood PLTs or PRP were recalcified with 5 mM 
CaCl2 and pretreated with 5 µM of control ODN, type C CpG ODN, 
or a vehicle control at 37°C for 10 min. Samples were perfused at a 
rate of 18.7 µl/min over a 300 µg/ml type IV collagen-coated or type I   
collagen-coated  (Takeda  Pharmaceuticals  International  GmbH)  perfu-
sion chambers (0.1 µ-Slide IV; ibidi) for 10 min. Images were collected 
on an inverted microscope (Axiovert 200) with a monochrome camera   
(AxioCam MRm; Carl Zeiss) and processed using the AxioVision LE soft-
ware package (Carl Zeiss).
Preparation of photomicrographs
The  digital  images  produced  in  MetaMorph  and  AxioVision  LE  were   
assembled into composite images by using ImageJ and Photoshop CS3 
(Invitrogen) or in mirVana (Ambion) lysis buffer. RNA was isolated as de-
scribed by each manufacturer, resuspended in RNase-free distilled H2O, 
and treated with reagent (TURBO DNase; Ambion). The DNase-treated 
RNA was precipitated with 3× vol ethanol and 1/10 vol sodium acetate 
followed by rigorous 70% ethanol washes. RNA integrity was evaluated 
on a bioanalyzer (2100 Bioanalyzer; Agilent Technologies), and samples 
with RNA integrity numbers >7.0 were used for sequencing. Poly(A)-tailed 
RNA was prepared by the University of Utah Core facility using the sample 
prep kit (mRNA-Seq Sample Prep; Illumina). All experiments complied with 
institutional guidelines approved by the Children’s Hospital animal care 
and use committee and the Institutional Animal Care and Use Committee.
Flow cytometry
Human/mouse PLTs were collected from whole blood and either (a) washed 
and examined under resting conditions or after activation (5 min at 37°C) 
with 1 mU/µl thrombin (Roche) or (b) isolated from PRP and examined 
under resting conditions or activation (5 min at 37°C) with 1 µM PMA 
(Sigma-Aldrich), 3 µg/ml CRP (Falet et al., 2010), 20 µM ADP (Bio/Data 
Corporation), or 50 µg/ml mouse type IV collagen (Gibco). Samples were 
probed with phycoerythrin (PE)-conjugated mouse anti-TLR9 antibodies   
(Imgenex) and one of the following: FITC-conjugated type C CpG (InvivoGen), 
FITC-conjugated mouse anti-CD62P antibodies, or FITC-conjugated mouse 
anti-CD61antibodies  (BD)  and  run  on  a  flow  cytometer  (FACSCalibur; 
BD). PLTs were gated by their characteristic forward and side scattering 
as they passed through the detector, and their total fluorescence intensity 
was calculated after subtraction of a PE- or FITC-conjugated IgG antibody 
specificity control (BD). Analyses of PLT mean fluorescence intensity were 
performed for at least three different samples. Where appropriate, data 
were subject to one-way analysis of variance (ANOVA) and Tukey hon-
estly significant difference (HSD) analysis. Error bars represent one stan-
dard deviation about the mean for at least three independent samples.
For examination of PLT activation, TLR9 and CD62P surface expres-
sion, and type C CpG sequestration, washed human PLTs were incubated 
for 0, 5, 10, 20, 40, and 60 min at 37°C with either 5 µM FITC-conjugated 
type C CpG (InvivoGen) or a vector control. Samples were immediately 
fixed in 4% formaldehyde and probed with PE-conjugated mouse anti-TLR9 
antibodies (Imgenex) or PE-conjugated mouse anti-CD61P antibodies (BD) 
before being run on a flow cytometer (FACSCalibur). PLTs were gated by 
their characteristic forward and side scattering as they passed through the 
detector, and the percentage of fluorescently conjugated PLT-sized events 
was calculated after subtraction of unlabeled type C CpG and FITC/ 
PE-conjugated IgG antibody specificity controls. For type IV collagen activa-
tion experiments, PLTs were preincubated with 50 µg/ml type IV collagen 
for 5 min at 37°C before addition of type C CpG. Analyses of TLR9 and 
CD62P surface expression and type C CpG sequestration were performed 
for at least four different samples. Where appropriate, data were subject to 
one-way ANOVA and Tukey HSD analysis. Error bars represent one stan-
dard deviation about the mean for at least three independent samples.
Immunofluorescence microscopy
MKs, pro-PLT–MKs, released pro-PLTs, and whole-blood PLTs were isolated 
as  described  in  MK  suspension  cultures.  For  type  C  CpG  endocytosis 
experiments  human  whole  blood–washed  PLTs  were  incubated  with  FITC- 
conjugated type C CpG (InvivoGen) at 37°C and 5% CO2 for a period of   
≤4 h. In brief, samples were fixed in 4% formaldehyde and centrifuged onto   
1 µg/ml poly-l-lysine–coated coverslips, permeabilized with 0.5% Triton 
X-100, and blocked in immunofluorescence blocking buffer (0.5 g BSA,   
0.25 ml of 10% sodium azide, and 5 ml FCS in 50 ml PBS) overnight before   
antibody labeling (Italiano et al., 2003). To demarcate permeabilized 
cells, samples were incubated with a rabbit polyclonal primary antibody for   
human or mouse 1-tubulin generated against the C-terminal peptide sequence 
CKAVLEEDEEVTEEAEMEPEDKGH  and  LEDSEEDAEEAEVEAEDKDH,  respec-
tively (Genemed Synthesis, Inc.). For granule localization, samples were in-
cubated with primary antibodies against TLR9 (Imgenex), VEGF, fibrinogen, 
CD62P, CD42a, PDGF-B (Santa Cruz Biotechnology, Inc.), CD42b (Dako), 
M6P, LAMP-1 (Abcam), Syntaxin-13 (a gift from A. Peden, University of 
Cambridge, Cambridge, England, UK), serotonin (EMD Millipore), or VAMPs 
5/7/8 (Novus Biologicals) alone or in combination. All samples were treated 
with a secondary goat anti–rabbit or mouse antibody conjugated to an Alexa 
Fluor 488 or 568 nm (Invitrogen; Molecular Probes). As background controls, 
slides were incubated with the appropriate secondary antibody alone, and 
all images were adjusted to account for nonspecific binding of antibodies. 
For granule localization experiments with known  or dense granule, lyso-
somal, and endosomal markers, samples were examined with a microscope 
(Axiovert 200; Carl Zeiss) equipped with a 63×, NA 1.4 Plan-Apochromat 573 Platelet TLR9 localization and function • Thon et al.
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